Answers are grounded in this paper and cite their sources.
Mixed-methods study explores treatment choices in relapsed multiple myeloma, highlighting clinical decision-making challenges.
e19525 Background: BCMA-directed CAR T cell therapies and bispecific antibodies (BsAbs) have transformed outcomes for patients with relapsed/refractory multiple myeloma (RRMM). As these therapies move earlier in treatment, an increasing proportion of patients relapse after exposure to one or both T-cell–redirecting modalities. Real-world evidence to guide treatment selection in this setting remains limited, creating uncertainty in clinical practice. Methods: A mixed-methods market research study surveyed 61 hematologist/oncologists from academic (43%, n = 26) and community (57%, n = 35) practices across the U.S. using a structured online questionnaire, supplemented by qualitative interviews conducted via web-based videoconferencing. Fieldwork occurred between October and November 2025. Quantitative measures assessed treatment patterns, sequencing strategies, access barriers, and real-world considerations influencing CAR T and BsAb use in RRMM using Likert-type scales and utilization metrics. Qualitative interviews followed a semi-structured guide exploring physician rationale for treatment selection, sequencing philosophies, and access-related decision-making. Results: Physicians consistently described relapse after CAR T or BsAbs as one of the most challenging aspects of RRMM management. While 56% preferred sequencing CAR T prior to BsAbs, real-world constraints often led to bispecific therapy being used first due to off-the-shelf availability. After progression, 67% reported no clear standard of care, relying on individualized decisions informed by prior response depth and durability, toxicity, performance status, and treatment availability. Re-treatment with an alternate T-cell–redirecting modality was commonly considered, though concerns regarding T-cell exhaustion, diminished efficacy, and cumulative toxicity were frequently cited. Some physicians favored non–T-cell–engaging regimens or clinical trial enrollment, particularly for frail or heavily pretreated patients. There was broad consensus that limited guidance and lack of strong efficacy data for post–T-cell–redirecting therapy represent a critical gap. Conclusions: As CAR T and BsAbs become foundational in RRMM, the lack of guidance for managing relapse after these therapies represents an emerging clinical gap. Physicians report heterogeneous, individualized approaches in the absence of a defined standard of care. Although CAR T remains preferred earlier in sequencing, real-world constraints frequently influence treatment order. These findings highlight the need for prospective studies and real-world evidence to clarify post–T-cell–redirecting therapy sequencing, inform clinical frameworks, support decision-making, and improve outcomes for patients with RRMM.
No takes yet. Share an insight, caveat, or question.
Hendry et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: